Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2010, Article ID 538589, 8 pages
http://dx.doi.org/10.1155/2010/538589
Review Article

Renal Manifestations in Scleroderma: Evidence for Subclinical Renal Disease as a Marker of Vasculopathy

Division of Rheumatology, Immunology and Allergy, Georgetown University Hospital, 3800 Reservoir Road, N.W, Washington, DC 20007, USA

Received 14 May 2010; Accepted 12 July 2010

Academic Editor: Eswar Krishnan

Copyright © 2010 Victoria K. Shanmugam and Virginia D. Steen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Helmick, D. T. Felson, R. C. Lawrence et al., “Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I,” Arthritis and Rheumatism, vol. 58, no. 1, pp. 15–25, 2008. View at Google Scholar
  2. D. J. Abraham, T. Krieg, J. Distler, and O. Distler, “Overview of pathogenesis of systemic sclerosis,” Rheumatology, vol. 48, supplement 3, pp. iii3–iii7, 2009. View at Google Scholar · View at Scopus
  3. E. C. LeRoy, C. Black, R. Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988. View at Google Scholar · View at Scopus
  4. V. D. Steen, “The many faces of scleroderma,” Rheumatic Disease Clinics of North America, vol. 34, no. 1, pp. 1–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Giordano, G. Valentini, S. Migliaresi et al., “Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis,” Journal of Rheumatology, vol. 13, no. 5, pp. 911–916, 1986. View at Google Scholar · View at Scopus
  6. K. M. Ingraham, M. S. O'Brien, M. A.X. Shenin, C. T. Derk, and V. D. Steen, “Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors,” The Journal of Rheumatology, vol. 37, no. 3, pp. 603–607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. V. D. Steen, “Scleroderma renal crisis,” Rheumatic Disease Clinics of North America, vol. 29, no. 2, pp. 315–333, 2003. View at Google Scholar · View at Scopus
  8. D. C. Trostle, C. D. Bedetti, V. D. Steen, M. R. Al-Sabbagh, B. Zee, and T. A. Medsger Jr., “Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 393–400, 1988. View at Google Scholar · View at Scopus
  9. P. J. Cannon, M. Hassar, D. B. Case, W. J. Casarella, S. C. Sommers, and E. C. LeRoy, “The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation,” Medicine, vol. 53, no. 1, pp. 1–46, 1974. View at Google Scholar · View at Scopus
  10. H. J. Anders, B. Wiebecke, C. Haedecke, S. Sanden, C. Combe, and D. Schlöndorff, “MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease?” American Journal of Kidney Diseases, vol. 33, no. 4, article e3, 1999. View at Google Scholar · View at Scopus
  11. G. S. Hillis, I. H. Khan, J. G. Simpson, and A. J. Rees, “Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies,” American Journal of Kidney Diseases, vol. 30, no. 2, pp. 279–281, 1997. View at Google Scholar · View at Scopus
  12. M. T. Kovalchik, S. J. Guggenheim, M. H. Silverman, J. Robertson, and J. Steigerwald, “The kidney in progressive systemic sclerosis. A prospective study,” Annals of Internal Medicine, vol. 89, no. 6, pp. 881–887, 1978. View at Google Scholar · View at Scopus
  13. V. D. Steen and T. A. Medsger Jr., “Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis,” Arthritis and Rheumatism, vol. 41, no. 9, pp. 1613–1619, 1998. View at Google Scholar · View at Scopus
  14. H. Penn, A. J. Howie, E. J. Kingdon et al., “Scleroderma renal crisis: patient characteristics and long-term outcomes,” QJM, vol. 100, no. 8, pp. 485–494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Teixeira, L. Mouthon, A. Mahr et al., “Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients,” Annals of the Rheumatic Diseases, vol. 67, no. 1, pp. 110–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. V. D. Steen and T. A. Medsger, “Changes in causes of death in systemic sclerosis, 1972–2002,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 940–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D. J. Helfrich, B. Banner, V. D. Steen, and T. A. Medsger Jr., “Normotensive renal failure in systemic sclerosis,” Arthritis and Rheumatism, vol. 32, no. 9, pp. 1128–1134, 1989. View at Google Scholar · View at Scopus
  18. H. Akoglu, G. K. Atilgan, R. Ozturk, E. C. Yenigun, I. I. Gonul, and A. R. Odabas, “A "silent" course of normotensive scleroderma renal crisis: case report and review of the literature,” Rheumatology International, vol. 29, no. 10, pp. 1223–1229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Mimura, Y. Hori, T. Matsukawa, H. Uozaki, A. Tojo, and T. Fujita, “Noncrescentic ANCA-associated renal crisis in systemic sclerosis,” Clinical Nephrology, vol. 70, no. 2, pp. 183–185, 2008. View at Google Scholar · View at Scopus
  20. H. Endo, T. Hosono, and H. Kondo, “Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis,” Journal of Rheumatology, vol. 21, no. 5, pp. 864–870, 1994. View at Google Scholar · View at Scopus
  21. C. T. Derk and S. A. Jimenez, “Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature,” The Journal of Rheumatology, vol. 30, no. 7, pp. 1616–1620, 2003. View at Google Scholar · View at Scopus
  22. P. A. Merkel, Y. Chang, S. S. Pierangeli, K. Convery, E. N. Harris, and R. P. Polisson, “The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases,” American Journal of Medicine, vol. 101, no. 6, pp. 576–583, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Parodi, M. Drosera, L. Barbieri, and A. Rebora, “Antiphospholipid antibody system in systemic sclerosis,” Rheumatology, vol. 40, no. 1, pp. 111–112, 2001. View at Google Scholar · View at Scopus
  24. L. Schoenroth, M. Fritzler, L. Lonzetti, and J.-L. Senécal, “Antibodies to β2 glycoprotein I and cardiolipin in SSc,” Annals of the Rheumatic Diseases, vol. 61, no. 2, pp. 183a–184a, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Wielosz, M. Dryglewska, and M. Majdan, “Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis,” Clinical Rheumatology, vol. 28, no. 8, pp. 955–959, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. E. J. Kingdon, C. J. Knight, K. Dustan et al., “Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment,” Rheumatology, vol. 42, no. 1, pp. 26–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Scheja, I. Bartosik, D. M. Wuttge, and R. Hesselstrand, “Renal function is mostly preserved in patients with systemic sclerosis,” Scandinavian Journal of Rheumatology, vol. 38, no. 4, pp. 295–298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. V. D. Steen, A. Syzd, J. P. Johnson, A. Greenberg, and T. A. Medsger Jr., “Kidney disease other than renal crisis in patients with diffuse scleroderma,” Journal of Rheumatology, vol. 32, no. 4, pp. 649–655, 2005. View at Google Scholar · View at Scopus
  29. R. H. Mohamed, H. S. Zayed, and A. Amin, “Renal disease in systemic sclerosis with normal serum creatinine,” Clinical Rheumatology, vol. 29, no. 7, pp. 729–737, 2010. View at Google Scholar
  30. A. Campo, S. C. Mathai, J. Le Pavec, A. L. Zaiman, L. K. Hummers, and D. Boyce, “Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 252–260, 2010. View at Google Scholar
  31. R. Livi, L. Teghini, A. Pignone, S. Generini, M. Matucci-Cerinic, and M. Cagnoni, “Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement,” Annals of the Rheumatic Diseases, vol. 61, no. 8, pp. 682–686, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. N. S. Anavekar, J. J.V. McMurray, E. J. Velazquez et al., “Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1285–1295, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population,” Circulation, vol. 106, no. 14, pp. 1777–1782, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. T. H. Hostetter, “The chronic kidney disease predicts cardiovascular disease,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1344–1346, 2004. View at Google Scholar · View at Scopus
  36. K. Klausen, K. Borch-Johnsen, B. Feldt-Rasmussen et al., “Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes,” Circulation, vol. 110, no. 1, pp. 32–35, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Seiberlich, N. Hunzelmann, T. Krieg, M. Weber, and E. Schulze-Lohoff, “Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity,” Clinical Nephrology, vol. 70, no. 2, pp. 110–117, 2008. View at Google Scholar · View at Scopus
  38. A. Dawnay, A. G. T. Wilson Mc., E. Lamb, J. D. T. Kirby, and W. R. Cattell, “Microalbuminuria in systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 51, no. 3, pp. 384–388, 1992. View at Google Scholar · View at Scopus
  39. G. Koliakos, F. Papachristou, M. Papadopoulou, V. Trachana, M. Gaitatzi, and I. Sotiriou, “Electrophoretic analysis of urinary proteins in diabetic adolescents,” Journal of Clinical Laboratory Analysis, vol. 15, no. 4, pp. 178–183, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Francois, G. Moulin, H. Assenat, B. Jandot, and R. Cahen, “The kidney in systemic scleroderma. A report of 38 consecutive cases,” Nephrologie, vol. 3, no. 2, pp. 85–91, 1982. View at Google Scholar · View at Scopus
  41. M. T. James, B. R. Hemmelgarn, and M. Tonelli, “Early recognition and prevention of chronic kidney disease,” The Lancet, vol. 375, no. 9722, pp. 1296–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. O. Gross, B. Beirowski, M.-L. Koepke et al., “Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome1,” Kidney International, vol. 63, no. 2, pp. 438–446, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. V. D. Steen and T. A. Medsger Jr., “Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis,” Arthritis and Rheumatism, vol. 41, no. 9, pp. 1613–1619, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Penn and C. P. Denton, “Diagnosis, management and prevention of scleroderma renal disease,” Current Opinion in Rheumatology, vol. 20, no. 6, pp. 692–696, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. J. F. Platt, J. M. Rubin, and J. H. Ellis, “Lupus nephritis: predictive value of conventional and Doppler US and comparison with serologic and biopsy parameters,” Radiology, vol. 203, no. 1, pp. 82–86, 1997. View at Google Scholar · View at Scopus
  46. C. Ogata, K. Kamide, Y. Suzuki et al., “Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade,” Clinical Nephrology, vol. 64, no. 5, pp. 352–357, 2005. View at Google Scholar · View at Scopus
  47. R. Rivolta, B. Mascagni, V. Berruti et al., “Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy,” Arthritis and Rheumatism, vol. 39, no. 6, pp. 1030–1034, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. C. P. Denton, G. Lapadula, L. Mouthon, and U. Müller-Ladner, “Renal complications and scleroderma renal crisis,” Rheumatology, vol. 48, supplement 3, pp. iii32–iii35, 2009. View at Google Scholar · View at Scopus
  49. R. Scorza, R. Rivolta, B. Mascagni et al., “Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis,” Journal of Rheumatology, vol. 24, no. 10, pp. 1944–1948, 1997. View at Google Scholar · View at Scopus
  50. P. Airò, M. Rossi, M. Scarsi, E. Danieli, A. Grottolo, and A. Zambruni, “Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group,” Clinical and Experimental Rheumatology, vol. 25, no. 5, pp. 722–727, 2007. View at Google Scholar · View at Scopus
  51. E. Rosato, R. Cianci, B. Barbano et al., “N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis,” Acta Pharmacologica Sinica, vol. 30, no. 9, pp. 1283–1288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Sochman and J. H. Peregrin, “Total recovery of left ventricular function after acute myocardial infarction: comprehensive therapy with streptokinase, N-acetylcysteine and percutaneous transluminal coronary angioplasty,” International Journal of Cardiology, vol. 35, no. 1, pp. 116–118, 1992. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Tian, R. A. Rose, S. Jordan, T. M. Dwyer, M. D. Hughson, and R. D. Manning Jr., “N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension,” Journal of Hypertension, vol. 24, no. 11, pp. 2263–2270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Sahin, A. U. Yalcin, and N. Akcar, “Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients,” Blood Purification, vol. 25, no. 4, pp. 309–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Fishbane, J. H. Durham, K. Marzo, and M. Rudnick, “N-acetylcysteine in the prevention of radiocontrast-induced nephropathy,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 251–260, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. T. A. Springer, “Adhesion receptors of the immune system,” Nature, vol. 346, no. 6283, pp. 425–434, 1990. View at Publisher · View at Google Scholar · View at Scopus
  57. C. P. Denton, M. C. M. Bickerstaff, X. Shiwen et al., “Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis,” Rheumatology, vol. 34, no. 11, pp. 1048–1054, 1995. View at Google Scholar · View at Scopus
  58. M. W. J. Boehme, W. H. Schmitt, P. Youinou, W. R. Stremmel, and W. L. Gross, “Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides,” American Journal of Medicine, vol. 101, no. 4, pp. 387–394, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Pigott, L. P. Dillon, I. H. Hemingway, and A. J. H. Gearing, “Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells,” Biochemical and Biophysical Research Communications, vol. 187, no. 2, pp. 584–589, 1992. View at Publisher · View at Google Scholar · View at Scopus
  60. R. J. Stratton, J. G. Coghlan, J. D. Pearson et al., “Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma,” QJM, vol. 91, no. 8, pp. 561–566, 1998. View at Google Scholar · View at Scopus